Author Information
Neil Canavan is a veteran journalist specializing in science and medicine, a career he embarked upon after earning a master's degree in molecular and cellular biodynamics from Rutgers University. With more than 15 years of reporting experience, and some 200 feature articles to his credit Neil has written for such news outlets as WebMD, Medscape, Drug Discovery and Development Magazine, and The Scientist. Currently, Neil is a contributing editor to The Oncology Business Review where he has written many articles on the technology of, and clinical outcomes for cancer immunotherapy.
Since 2014 Neil has held the position of Scientific Advisor at The Trout Group, a New York-based investor relations firm focused on healthcare biotechnology. The Trout Group has 30 clients in the oncology space, with many of those companies pursuing the development of cancer immunotherapies.
Contributors:
James Allison, Ph.D.
Professor, Chair of Immunology
M.D. Anderson Cancer Center
Houston, TX
Jedd Wolchok, M.D., Ph.D.
Chief, Melanoma & Immunotherapeutics
Memorial Sloan Kettering Cancer Center
New York, NY
Axel Hoos, M.D., Ph.D.
Head, Therapeutic Area Oncology & Immuno-Oncology
GlaxoSmithKline Pharmaceuticals
Collegeville, PA
Tasuku Honjo, M.D., Ph.D.
Professor, Department of Immunology and Genomic Medicine
Kyoto University
Kyoto, Japan
Gordon Freeman, Ph.D.
Professor of Medicine
Harvard Medical School
Boston, MA
Suzanne L. Topalian, M.D.
Professor, Surgery and Oncology
Director, Melanoma Program, Kimmel Cancer Center
Johns Hopkins University
Baltimore, MD
Robert Schreiber, Ph.D.
Director, Center for Human Immunology and Immunotherapy Programs
Washington University School of Medicine
St. Louis, MO
Drew Pardoll, M.D., Ph.D.
Co-Director, Cancer Immunology and Hematopoiesis Program
Professor of Oncology
Johns Hopkins University
Baltimore, MD
Elizabeth Jaffee, M.D.
Deputy Director, Sidney Kimmel Comprehensive Cancer Center
Co-Director, Cancer Immunology Program
John Hopkins University
Baltimore, MD
Ralph Steinman, M.D.
Tak Mak, Ph.D.
Senior Scientist
Princess Margaret Cancer Centre
Toronto, Canada
Philip Greenberg, M.D.
Head, Program in Immunology
Professor of Medicine and Immunotherapy
University of Washington, Seattle
Steven Rosenberg M.D., Ph.D.
Chief, Surgery Branch
Head, Tumor Immunology Section
National Cancer Institute, NIH
Washington, DC
Zelig Eshhar, Ph.D.
Professor of Chemical and Cellular Immunology
Weizmann Institute of Science
Patrick Hwu, M.D.
Department Chair, Department of Melanoma Medical Oncology
Division of Cancer Medicine
The University of Texas M.D. Anderson Cancer Center
Houston, TX
Capt. Carl June, M.D. (Ret.)
Director, Translational Research Program
Abramson Cancer Center, Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA
Michel Sadelain, M.D., Ph.D.
Director, Center for Cell Engineering & Gene Transfer and Gene Expression Laboratory
Stephen and Barbara Friedman Chair
Memorial Sloan Kettering Cancer Center
New York, NY
Patrick Baeuerle, Ph.D.
Managing Director
MPM Capital
Boston, MA
Robert Coffin, Ph.D.
Cofounder, CEO
Replimune
Woburn, MA
Shimon Sakaguchi M.D., Ph.D.
Distinguished Professor
Department of Experimental Immunology
Osaka University
Osaka, Japan
Jeff Bluestone, Ph.D.
Clausen Distinguished Professor of Metabolism and Endocrinology
President and CEO of the Parker Institute for Cancer Immunotherapy
University of California, San Francisco
David Munn, M.D.
Cancer Immunology, Inflammation and Tolerance Program
Professor of Pediatrics
Augusta University
Augusta, GA
Dmitry Gabrilovich, M.D., Ph.D.
Program Leader, Translational Tumor Immunology Program
The Wistar Institute
Philadelphia, PA
Tom Gajewski, M.D., Ph.D.
Professor of Pathology and Medicine
University of Chicago
Chicago, IL
Laurence Zitvogel, M.D., Ph.D.
Research Director, Tumour Immunology and Immunotherapy
Gustave Roussy Cancer Center
Villejuif, France